Ginzburg explained why it is too early to talk about a cure for cancer vaccine
The first patient has completed a course of treatment with a vaccine against melanoma, the head of the center told TASS.
The first patient completed a course of treatment with a vaccine against melanoma, the scientific director of the N. F. Gamalei Center Alexander Ginzburg told TASS.
He noted that the patient has no metastases, but it is too early to talk about his complete cure. “The absence of metastases does not mean a complete cure, a cure for cancer is 5 years of observations, there were no 5 years, now 5 months are just coming,” he explained.
As Ginzburg emphasized, that is why the Ministry of Health will continue to monitor patients who have completed treatment with oncological vaccine.
The first patient received the personalized antitumor mRNA vaccine Neonkovak for the treatment of skin melanoma in April 2026. The drug was developed jointly with the Gamalea Center. The vaccine is made individually for each patient, it must adjust the immune system to recognize and destroy tumor cells.
